🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

14,283 results for “B” Clear

  1. FAMPRIDINE, Placebo 515

    Pari Pharma GmbH

    Spinocerebellar ataxia

    phase 3 small molecule active

    1 trial

  2. FE 999326

    Ferring Pharmaceuticals

    Bladder Cancer

    phase 3 small molecule active

    1 trial

  3. FE 999913 vaginal tablet

    Ferring Pharmaceuticals

    Luteal Hormone Supplementation

    phase 3 small molecule completed

    1 trial

  4. FEIBA

    Takeda

    Hemophilia A or B With Inhibitors

    phase 3 mab completed

    1 trial

  5. FF/GW642444 Inhalation Powder

    GlaxoSmithKline

    Pulmonary Disease, Chronic Obstructive

    phase 3 small molecule completed

    2 trials

  6. FIBRINOGEN, HUMAN, RIVAROXABAN , APIXABAN , ETAMSYLATE , TRANEXAMIC ACID , -, PROTAMINE , -, ERYTHROCYTES , AMINOMETHYLBENZOIC ACID , -, AMINOCAPROIC ACID , Ondexxya 200 mg powder for solution for infusion, EDOXABAN , -

    AstraZeneca AB

    Reversal of anticoagulation effect in patients on a FXa inhibitor (apixaban, rivaroxaban, or edoxaban) who require urgent surgery or procedure, and who have a major risk of bleeding.

    phase 3 small molecule active

    1 trial

  7. FILGRASTIM, CYCLOPHOSPHAMIDE, DOXORUBICIN, DEXRAZOXANE HYDROCHLORIDE

    Ningbo Cancer Hospital

    Advanced or metastatic soft tissue sarcoma (STS) in patients ≥65 years old

    phase 3 small molecule active

    1 trial

  8. FKB238 (bevacizumab)

    Centus Biotherapeutics Europe Limited

    Carcinoma, Non-Small-Cell Lung

    phase 3 small molecule completed

    1 trial

  9. FLECAINIDE

    Pari Pharma GmbH

    Patent Foramen Ovale Closure Atrial Arrhytmia or Tachycardia

    phase 3 small molecule active

    1 trial

  10. FLORTAUCIPIR (18F), FLORTAUCIPIR (18F), FLORBETAPIR (18F), FLORBETAPIR (18F)

    The George Institute

    Semantic Variant Primary Progressive Aphasia, Alcohol Use Disorder, Organic amnesia syndrome, Narcolepsy, Alzheimer, Lewy Body Dementia

    phase 3 small molecule active

    1 trial

  11. FLUCONAZOLE , SULFAMETHOXAZOLE AND TRIMETHOPRIM , AMOXICILLIN , METRONIDAZOLE , CIPROFLOXACIN , AMOXICILLIN AND BETA-LACTAMASE INHIBITOR , CLINDAMYCIN , DOXYCYCLINE , LINEZOLID , SODIUM CHLORIDE SOLUTION 0.9%

    The George Institute

    Patients with hip or knee infections

    phase 3 small molecule active

    1 trial

  12. FLUDARABINE PHOSPHATE, DAUNORUBICIN HYDROCHLORIDE, BUSULFAN, Azacitidine Accord 25 mg/mL powder for suspension for injection, CYTARABINE, THIOTEPA

    Fondazione Telethon ETS

    Higher-risk-myelodysplastic syndromes

    phase 3 small molecule active

    1 trial

  13. FLUOROURACIL , CAPECITABINE , Folikabi 10 mg/ml oplossing voor injectie/infusie, OXALIPLATIN

    Disc Medicine

    Rectal cancer

    phase 3 small molecule active

    1 trial

  14. FLUOROURACIL , OXALIPLATIN , GEMCITABINE , FOLIC ACID

    Pari Pharma GmbH

    Pancreatic adenocarcinoma (PAC)

    phase 3 small molecule active

    1 trial

  15. FLUOROURACIL, BEVACIZUMAB, FOLINIC ACID, OXALIPLATIN, ivonescimab

    Summit Therapeutics

    Metastatic colorectal cancer

    phase 3 small molecule active

    1 trial

  16. FLUOROURACIL, CAPECITABINE, Zimberelimab, OXALIPLATIN, FLUOROURACIL, CALCIUM FOLINATE, DOMVANALIMAB, NIVOLUMAB, FLUOROURACIL, CAPECITABINE

    Arcus Biosciences

    Metastatic Esophageal or Gastric Cancer, Esophageal or Gastric Cancer

    phase 3 small molecule active

    1 trial

  17. FLUOROURACIL, CISPLATIN, CAPECITABINE, CISPLATIN, TRASTUZUMAB, Placebo for Pembrolizumab, OXALIPLATIN, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CAPECITABINE, TRASTUZUMAB

    Merck Sharp and Dohme

    Gastric or gastroesophageal junction (GEJ) adenocarcinoma

    phase 3 small molecule active

    1 trial

  18. FLUOROURACIL, DOCETAXEL, OPDIVO 10 mg/mL concentrate for solution for infusion., OXALIPLATIN, CALCIUM LEVOFOLINATE, CISPLATIN, DOXORUBICIN HYDROCHLORIDE

    Verona Pharma Ireland Limited

    Gastric adenocarcinoma with peritoneal metastases

    phase 3 small molecule active

    1 trial

  19. FLUTICASONE , Dupilumab, SALBUTAMOL , BUDESONIDE , MONTELUKAST , Matched placebo for test (dupilumab low dose), Matched placebo for test (dupilumab high dose), BECLOMETASONE , Dupilumab, SALMETEROL AND FLUTICASONE

    Sanofi-aventis Healthcare Pty Ltd

    Respiratory tract diseases - Wheezing, Asthma

    phase 3 small molecule active

    1 trial

  20. FOSFOMYCIN , SULFAMETHOXAZOLE AND TRIMETHOPRIM

    Tour Hekla

    Benign Prostate Hyperplasia

    phase 3 small molecule active

    1 trial

  21. FS MDPI

    Teva Pharma GmbH

    Asthma

    phase 3 small molecule completed

    2 trials

  22. FULVESTRANT , EXEMESTANE , ABEMACICLIB

    Eli Lilly Co.

    Breast Cancer

    phase 3 small molecule active

    1 trial

  23. FUROSEMIDE , DULOXETINE

    Ningbo Cancer Hospital

    ER positive HER2 negative breast cancer stages I-II

    phase 3 small molecule active

    1 trial

  24. Fabrazyme 35 mg powder for concentrate for solution for infusion, venglustat GZ402671 - SAR402671, Replagal 1 mg/ml concentrate for solution for infusion., Replagal 1 mg/ml concentrate for solution for infusion., Galafold 123 mg hard capsules, Replagal 1 mg/ml concentrate for solution for infusion.

    Sanofi-aventis Healthcare Pty Ltd

    Fabry’s disease

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources